High-Fidelity Eukaryotic Protein Expression for Complex and Sensitive Targets. Mammalian proteins often require sophisticated chaperone-assisted folding and specific regulatory environments that microbial systems cannot replicate. CD Biosynsis provides professional Rabbit Reticulocyte Lysate (RRL) System CFPS Services, utilizing one of the most established and high-fidelity eukaryotic in vitro translation platforms. Our RRL system leverages endogenous mammalian translational machinery to produce proteins with native-like structural integrity. Whether you are synthesizing delicate membrane proteins or complex multi-subunit assemblies, our RRL platform offers a rapid, "open-system" solution to bypass the limitations of living cell cultures.
Get a Technical QuoteOur RRL platform provides a versatile eukaryotic environment for the synthesis of diverse protein classes, optimized for both research and industrial applications. We focus on bridging the gap between digital design and functional mammalian protein reality.
| Service Tier | Technical Focus | Primary Application | Industrial/Research Value |
|---|---|---|---|
| Complex Mammalian Synthesis | High-fidelity eukaryotic translation | Human enzymes & Ribosomal proteins | Preserves native structural integrity |
| Membrane Protein Platform | Hydrophobic stabilization environment | GPCRs & Ion Channels | Produces functional drug-target receptors |
| Quaternary Structure & Assembly | Multi-subunit protein organization | Vaccine development (VLPs) & Virology | Enables complex protein self-assembly |
| System Tuning & High-Yield | Translational enhancer integration | Pilot-scale assays & Diagnostics | Overcomes traditional yield bottlenecks |
| Toxic Protein Expression | Toxicity-tolerant synthesis | Bioactive peptides & Regulatory factors | Bypasses host cell viability constraints |
1. Sequence Optimization
2. Customized Formulation
3. Controlled Synthesis
4. Native Validation
Optimizing genetic templates for mammalian translational efficiency, including strategic use of IRES or viral motifs.
Formal project proposal and Mutual NDA signing.
Tailoring the RRL environment with specific additives like microsomal membranes or specialized tRNAs.
Adjusting the physiochemical conditions to match the folding requirements of the target protein.
Executing the coupled transcription-translation reaction in a highly regulated eukaryotic environment.
Real-time monitoring and parallel synthesis of multiple genetic variants if required.
Gentle purification followed by comprehensive assessment of protein folding, activity, and purity.
Final delivery of functional proteins and detailed characterization dossiers.
To deliver world-class results, our technical team monitors and benchmarks our protocols against landmark research.
Structural human proteins require high-fidelity translation. Technical benchmarks have shown that RRL successfully expresses and stabilizes complex human ribosomal proteins (SA, S2, S3, S4X, S6, and S7), preserving their structurally conserved eukaryotic characteristics.
(Reference: Abstract 2094, RRL Human Expression, 2024)
GPCRs frequently fail in cell-based systems due to membrane toxicity. Research has proven that RRL provides an ideal environment for synthesizing high-purity, functional GPCRs. This "open system" approach facilitates the production of receptors ready for drug target screening.
(Reference: Functional GPCR Synthesis, 2020)
Studying virus assembly requires supporting quaternary organization. Utilizing RRL to express Hepatitis B core antigens (HBc), researchers successfully observed the self-assembly of these proteins into VLPs, highlighting RRL's capability in complex eukaryotic protein assembly.
(Reference: HBc Self-assembly in RRL, 2021)
To address yield limitations, methodologies involving NS1 proteins and Internal Ribosome Entry Sites (IRES) have been implemented. These strategies have shown to increase protein yields in RRL by more than 10-fold, providing a viable path for large-scale functional assays.
(Reference: Yield Optimization in RRL, 2021)
Ready to leverage the high-fidelity of mammalian cell-free synthesis?
Contact Us1. Why should I use RRL instead of a standard mammalian cell line?
RRL is much faster and more controllable. It allows for the expression of proteins toxic to cells and provides direct access to add stabilizers (like nanodiscs) that cannot be easily introduced into living cultures.
2. Can the RRL system handle complex post-translational modifications (PTMs)?
The basic lysate has limited PTM capacity. However, we can supplement the reaction with canine pancreatic microsomal membranes to support co-translational translocation and core glycosylation.
3. What is the typical yield for a standard RRL reaction?
Yields vary by protein, but our optimized system with IRES and viral enhancers can achieve yields ranging from several μg to mg per milliliter, sufficient for most structural and functional assays.
4. Is the RRL system suitable for high-throughput (HTP) screening?
Absolutely. Because it eliminates the need for cell expansion and colony selection, RRL is ideal for screening hundreds of genetic variants or protein mutants in parallel.
5. How do you verify that a synthesized GPCR is functional?
We perform binding assays and specialized structural characterizations to confirm the receptor has correctly inserted into mimetic membranes and retains its native-like ligand affinity.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.